Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

neonatal epilepsy syndrome - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

neonatal epilepsy syndrome

MONDO:0020070

Overview

An epilepsy syndrome that has an onset during the neonatal stage of life.

OnsetCONGENITAL

ResearchLimited published research (2 articles)

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

No HPO annotations are available for this condition.

Age of onset: at birth.

GeneReviews

Clinical Guidance

MECP2 duplication syndrome is an X-linked disorder, mainly affecting males. The core phenotype includes developmental delay / intellectual disability, infantile hypotonia, speech and motor delay, recurrent infections, seizures, and gastrointestinal dysfunction. Additional, less frequent clinical features have been described. More than 300 affected males have been reported to date and the clinical findings are consistent in all reports [, , , , , , , , , , , , , , , , ]. Table 2. Select Features of MECP2 Duplication Syndrome

Diagnosis

Drawn from GeneReviews diagnostic guidelines, newborn screening panel status (RUSP), and ClinGen gene-disease validity classifications. Reflects current clinical evidence and consensus where available.

GeneReviews

Diagnostic Criteria

Suggestive Findings

MECP2 duplication syndrome should be considered in males with the following clinical findings:

Severe-to-profound intellectual disability with limited or absent speech
Early-onset hypotonia with very slow motor development
Progressive spasticity predominantly of the lower limbs

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for neonatal epilepsy syndrome. The disease remains an area of unmet medical need.

GeneReviews

Management Guidelines

Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with MECP2 duplication syndrome, the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended. Table 3. Recommended Evaluations Following Initial Diagnosis in Individuals with MECP2 Duplication Syndrome

Prognosis

Based on GeneReviews surveillance recommendations, HPO phenotype frequency and severity annotations, and published prevalence estimates from Orphanet and OMIM.

GeneReviews

Surveillance Guidelines

Table 5.

Recommended Surveillance for Individuals with MECP2 Duplication Syndrome

System/Concern | Evaluation | Frequency

Feeding

| • Measurement of growth parameters

Eval of nutritional status safety of oral intake

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for neonatal epilepsy syndrome.

2 publications have been identified in PubMed for neonatal epilepsy syndrome. Research spans Review / Meta-Analysis (100%).

Recent Publications

Marques PT (2025). [PMID: 39944415](https://pubmed.ncbi.nlm.nih.gov/39944415/). *Neurol Genet*. [Review / Meta-Analysis]
Pepe G (2024). [PMID: 39544232](https://pubmed.ncbi.nlm.nih.gov/39544232/). *Front Endocrinol (Lausanne)*. [Review / Meta-Analysis]

Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 1:00 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:98257

GARD

Genetic and Rare Diseases Info Center

GARD:19435

Questions for Your Care Team

→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Feature	% of MALES w/Feature	Comment
Intellectual disability	100%	Most males have moderate-to-severe intellectual disability.
Infantile hypotonia	95%	—
Feeding issues	60%	—
Constipation	61%	—
Walk independently or w/support	55%	—
Spasticity	65%	Can be an underestimation given that this feature is age related
Seizures	~50%	—
Recurrent infections	75%	Most often affecting the respiratory tract
Nonspecific anomalies on brain imaging	69%	Feeding/gastrointestinal manifestations. During the first weeks of life, feeding difficulties resulting from hypotonia may become evident in affected males.

Kisho

neonatal epilepsy syndrome

Overview

Clinical Presentation

Clinical Guidance

Diagnosis

Diagnostic Criteria

Suggestive Findings

Treatment

Management Guidelines

Prognosis

Surveillance Guidelines

Feeding

Research Landscape

Recent Publications

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Differential Diagnosis

Therapies Under Investigation

Clinical Trials

Gastrointestinal

Development

Musculoskeletal

Neurologic

Immunologic

Behavioral

Other

neonatal epilepsy syndrome

Overview

Clinical Presentation

Clinical Guidance

Diagnosis

Diagnostic Criteria

Suggestive Findings

Treatment

Management Guidelines

Prognosis

Surveillance Guidelines

Feeding

Research Landscape

Recent Publications

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Differential Diagnosis

Therapies Under Investigation

Clinical Trials

Gastrointestinal

Development

Musculoskeletal

Neurologic

Immunologic

Behavioral

Other